Sonoma Pharmaceuticals (SNOA) Competitors $3.02 +0.01 (+0.33%) Closing price 08/6/2025 03:59 PM EasternExtended Trading$2.76 -0.27 (-8.77%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNOA vs. RLMD, PASG, CASI, CMMB, FNCH, RLYB, SYBX, LPCN, MBRX, and LEXXShould you be buying Sonoma Pharmaceuticals stock or one of its competitors? The main competitors of Sonoma Pharmaceuticals include Relmada Therapeutics (RLMD), Passage Bio (PASG), CASI Pharmaceuticals (CASI), Chemomab Therapeutics (CMMB), Finch Therapeutics Group (FNCH), Rallybio (RLYB), Synlogic (SYBX), Lipocine (LPCN), Moleculin Biotech (MBRX), and Lexaria Bioscience (LEXX). These companies are all part of the "pharmaceutical products" industry. Sonoma Pharmaceuticals vs. Its Competitors Relmada Therapeutics Passage Bio CASI Pharmaceuticals Chemomab Therapeutics Finch Therapeutics Group Rallybio Synlogic Lipocine Moleculin Biotech Lexaria Bioscience Relmada Therapeutics (NASDAQ:RLMD) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends. Does the media favor RLMD or SNOA? In the previous week, Relmada Therapeutics had 1 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 1 mentions for Relmada Therapeutics and 0 mentions for Sonoma Pharmaceuticals. Relmada Therapeutics' average media sentiment score of 0.00 equaled Sonoma Pharmaceuticals'average media sentiment score. Company Overall Sentiment Relmada Therapeutics Neutral Sonoma Pharmaceuticals Neutral Which has higher earnings and valuation, RLMD or SNOA? Sonoma Pharmaceuticals has higher revenue and earnings than Relmada Therapeutics. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRelmada TherapeuticsN/AN/A-$79.98M-$2.51-0.24Sonoma Pharmaceuticals$14.29M0.35-$3.46M-$3.10-0.97 Which has more volatility & risk, RLMD or SNOA? Relmada Therapeutics has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Comparatively, Sonoma Pharmaceuticals has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Do insiders & institutionals believe in RLMD or SNOA? 45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 20.7% of Relmada Therapeutics shares are held by insiders. Comparatively, 24.6% of Sonoma Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is RLMD or SNOA more profitable? Relmada Therapeutics has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -24.23%. Sonoma Pharmaceuticals' return on equity of -58.73% beat Relmada Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Relmada TherapeuticsN/A -181.26% -151.23% Sonoma Pharmaceuticals -24.23%-58.73%-21.05% Do analysts rate RLMD or SNOA? Relmada Therapeutics currently has a consensus price target of $5.00, indicating a potential upside of 734.72%. Given Relmada Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Relmada Therapeutics is more favorable than Sonoma Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relmada Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25Sonoma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryRelmada Therapeutics beats Sonoma Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get Sonoma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNOA vs. The Competition Export to ExcelMetricSonoma PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.94M$2.52B$5.56B$9.47BDividend YieldN/A1.78%4.31%4.17%P/E Ratio-0.9719.5129.3723.99Price / Sales0.35695.09444.7496.71Price / CashN/A162.3535.8458.51Price / Book1.115.208.085.58Net Income-$3.46M$31.61M$3.26B$265.35M7 Day Performance1.34%0.90%0.44%-0.07%1 Month Performance-4.13%6.97%4.82%1.76%1 Year Performance991.83%6.15%30.27%25.39% Sonoma Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNOASonoma PharmaceuticalsN/A$3.02+0.3%N/A+906.7%$4.94M$14.29M-0.97180Positive NewsRLMDRelmada Therapeutics4.5957 of 5 stars$0.64+0.2%$5.00+678.8%-81.5%$21.31MN/A-0.2610PASGPassage Bio3.3885 of 5 stars$6.82-3.3%$150.00+2,101.0%-65.9%$21.15MN/A-0.33130News CoverageUpcoming EarningsGap UpCASICASI Pharmaceuticals3.9745 of 5 stars$1.71+5.2%$4.00+134.6%-73.7%$20.97M$28.54M-0.67180News CoverageCMMBChemomab Therapeutics2.1658 of 5 stars$1.10+0.8%$8.50+673.4%-5.8%$20.73MN/A-1.4520Gap UpFNCHFinch Therapeutics GroupN/A$12.50-0.4%N/A+294.6%$20.08MN/A-1.42190Gap DownRLYBRallybio1.9592 of 5 stars$0.48-5.7%$10.00+2,005.3%-56.0%$19.77M$640K-0.4440Negative NewsUpcoming EarningsGap DownSYBXSynlogic0.9951 of 5 stars$1.62-0.3%N/A-17.9%$18.90M$10K-0.6480News CoverageUpcoming EarningsLPCNLipocine2.6679 of 5 stars$3.36-1.2%$9.00+167.9%-41.0%$17.97M$11.20M-3.2910Earnings ReportMBRXMoleculin Biotech2.6926 of 5 stars$0.60+8.7%$4.00+568.9%-70.2%$17.95MN/A0.0020News CoverageUpcoming EarningsShort Interest ↑Gap UpLEXXLexaria Bioscience2.8719 of 5 stars$0.90+1.0%$4.00+342.5%-76.2%$17.68M$615.92K-1.357Gap Up Related Companies and Tools Related Companies Relmada Therapeutics Competitors Passage Bio Competitors CASI Pharmaceuticals Competitors Chemomab Therapeutics Competitors Finch Therapeutics Group Competitors Rallybio Competitors Synlogic Competitors Lipocine Competitors Moleculin Biotech Competitors Lexaria Bioscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNOA) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonoma Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonoma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNOA Stock Alerts